These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Malherbe P; Borroni E; Gobbi L; Knust H; Nettekoven M; Pinard E; Roche O; Rogers-Evans M; Wettstein JG; Moreau JL Br J Pharmacol; 2009 Apr; 156(8):1326-41. PubMed ID: 19751316 [TBL] [Abstract][Full Text] [Related]
8. Visualizing differences in ligand-induced beta-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors. Evans NA; Groarke DA; Warrack J; Greenwood CJ; Dodgson K; Milligan G; Wilson S J Neurochem; 2001 Apr; 77(2):476-85. PubMed ID: 11299310 [TBL] [Abstract][Full Text] [Related]
9. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Coleman PJ; Cox CD; Roecker AJ Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591 [TBL] [Abstract][Full Text] [Related]
10. [Receptors for oreksins: structure, localisation and activation mechanisms]. Abramova TV; Perekrest SV; Shainidze KZ; Novikova NS; Korneva EA Ross Fiziol Zh Im I M Sechenova; 2011 Sep; 97(9):995-1007. PubMed ID: 22165210 [TBL] [Abstract][Full Text] [Related]
11. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. Boss C; Brisbare-Roch C; Jenck F J Med Chem; 2009 Feb; 52(4):891-903. PubMed ID: 19199652 [No Abstract] [Full Text] [Related]
13. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists. Jiang R; Song X; Bali P; Smith A; Bayona CR; Lin L; Cameron MD; McDonald PH; Kenny PJ; Kamenecka TM Bioorg Med Chem Lett; 2012 Jun; 22(12):3890-4. PubMed ID: 22617492 [TBL] [Abstract][Full Text] [Related]
14. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075 [TBL] [Abstract][Full Text] [Related]
15. Orexin receptor antagonists: a new concept in CNS disorders? Gatfield J; Brisbare-Roch C; Jenck F; Boss C ChemMedChem; 2010 Aug; 5(8):1197-214. PubMed ID: 20544785 [No Abstract] [Full Text] [Related]
16. Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. El Firar A; Voisin T; Rouyer-Fessard C; Ostuni MA; Couvineau A; Laburthe M FASEB J; 2009 Dec; 23(12):4069-80. PubMed ID: 19661287 [TBL] [Abstract][Full Text] [Related]
18. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Malherbe P; Roche O; Marcuz A; Kratzeisen C; Wettstein JG; Bissantz C Mol Pharmacol; 2010 Jul; 78(1):81-93. PubMed ID: 20404073 [TBL] [Abstract][Full Text] [Related]
19. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach. Hoyer D; Bartfai T Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity of orexin-A binding to phospholipase C inhibitors, neuropeptide Y, and secretin. Kane JK; Tanaka H; Parker SL; Yanagisawa M; Li MD Biochem Biophys Res Commun; 2000 Jun; 272(3):959-65. PubMed ID: 10860858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]